# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Johnny Cash (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML004-SYN
- Date: 2026-03-27
- Fictional facility: St. Posthumous Health Center
- Fictional author: Gideon Hale, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Endocrinology consultation and four-week diabetes check: lightheadedness on standing and choice of add-on glucose-lowering therapy. **S**

## History of present illness

Mr. Cash is a 71-year-old man with type 2 diabetes, autonomic and peripheral neuropathy, and severe primary open-angle glaucoma, seen four weeks after his first visit for an endocrinology consultation on the same day as his diabetes check. Metformin was raised to 1000 mg twice daily, atorvastatin was started, and dorzolamide was added to latanoprost four weeks ago. He takes all of them, and metformin causes no stomach upset. His fasting home glucose readings run 140 to 170 mg/dL, with none below 70. He now stands up in stages, has raised the head of his bed, wears waist-high compression, and drinks about 2 liters a day. He is still lightheaded on standing most mornings and after meals, but he has had no further falls since the first visit. He asks again what he really has, since he was once told it was Shy-Drager syndrome. **S**

| Element | Detail |
|---|---|
| Interval change | Lightheaded on standing most mornings and after meals; no further falls |
| Medication tolerance | No stomach upset on metformin 1000 mg twice daily; no muscle aches on atorvastatin; no eye stinging on dorzolamide |
| Home glucose | Fasting 140 to 170 mg/dL; none below 70 |
| Non-drug measures | Staged standing, head of bed raised, waist-high compression, 2 liters of fluid a day |
| Patient question | What is causing the lightheadedness |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight down 1 kg; no fever |
| Cardiovascular | Positive | Lightheaded on standing, worse in the morning and after meals; no fainting, chest pain, or palpitations |
| Gastrointestinal | Negative | No nausea, diarrhea, or early fullness |
| Genitourinary | Negative | No difficulty passing urine |
| Neurological | Positive | Numb feet to the ankles, unchanged; weak legs |
| Endocrine | Negative | No shakiness, sweating, or confusion suggesting low glucose |

6 systems reviewed. **S**

## Current medications

- Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals **S**
- Sitagliptin 100 mg oral tablet, one tablet by mouth daily **S**
- Atorvastatin 40 mg oral tablet, one tablet by mouth daily **S**
- Latanoprost 0.005% ophthalmic solution, one drop in each eye at bedtime **S**
- Dorzolamide 2% ophthalmic solution, one drop in each eye twice daily **S**
- Midodrine 2.5 mg oral tablet, one tablet by mouth three times daily, last dose by 6 PM **S**

## Allergies

- No known allergy **S**

## Objective

BP 142/78 mmHg; pulse 76 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 95% on room air; weight 95 kg; BMI 26.9 kg/m². All vital signs are synthetic.

Sodium: 139 mmol/L; Potassium: 4.3 mmol/L; Creatinine: 1.06 mg/dL; eGFR: 72 mL/min/1.73 m²; Glucose: 152 mg/dL (high). All results are synthetic.

## Change since baseline

- Sodium: 138 mmol/L at baseline, 139 mmol/L at this visit **S**
- Potassium: 4.4 mmol/L at baseline, 4.3 mmol/L at this visit **S**
- Creatinine: 1.04 mg/dL at baseline, 1.06 mg/dL at this visit **S**
- eGFR: 74 mL/min/1.73 m² at baseline, 72 mL/min/1.73 m² at this visit **S**
- Glucose: 186 mg/dL (high) at baseline, 152 mg/dL (high) at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Alert and wry; walks in with a cane |
| Cardiovascular | Regular rhythm; blood pressure 150/84 mmHg lying, 142/78 mmHg seated, and 110/68 mmHg after three minutes standing, with heart rate 76 rising only to 80, and lightheadedness |
| Feet | Skin intact; no ulcers or calluses; monofilament and vibration sensation reduced to the ankles; pedal pulses present |
| Neurological | Reduced ankle reflexes; stocking sensory loss in both legs |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Neurogenic orthostatic hypotension from diabetic autonomic neuropathy** (I95.1). A fall of 32 mmHg in systolic pressure on standing with a rise of only 4 beats per minute in heart rate shows a neurogenic cause. With long-standing diabetes and length-dependent sensory loss in both legs, the pattern fits diabetic autonomic neuropathy, and the earlier Shy-Drager label is not carried forward in this record. He is still symptomatic despite non-drug measures, and lying pressure is 150/84 mmHg. **S**
   - Start midodrine 2.5 mg on waking, at midday, and mid-afternoon, with the last dose at least four hours before bed.
   - Continue staged standing, head-of-bed elevation, compression, and fluids.
   - Check lying, seated, and standing pressure at each visit.
2. **Type 2 diabetes with diabetic autonomic neuropathy** (E11.43). HbA1c 8.6% four weeks ago, above his goal below 7.5%; fasting readings 140 to 170 on full-dose metformin. Sulfonylureas and insulin are avoided because autonomic neuropathy may blunt the warning signs of low glucose. eGFR 72 allows full-dose sitagliptin. Seated pressure is above 130/80, but with orthostatic hypotension no blood pressure medicine is used. **S**
   - Start sitagliptin 100 mg daily.
   - Continue metformin 1000 mg twice daily.
   - HbA1c at the three-month review.
3. **Diabetic peripheral neuropathy with loss of protective sensation** (E11.42). No ulcer or pre-ulcerative lesion. **S**
   - Daily foot checks and protective shoes.
4. **Primary open-angle glaucoma, severe stage** (H40.1133). Dorzolamide added four weeks ago; no eye pressure check has been made since. **S**
   - Ask the eye clinic for a pressure check as soon as possible.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Basic metabolic panel | Before choosing add-on therapy; yearly when eGFR is 60 or more | Completed today | eGFR 72 and potassium 4.3: no dose change needed for metformin or sitagliptin, and safe to start midodrine |
| Laboratory | HbA1c | Every 3 months until at goal or after a therapy change; every 6 months when stable | Up to date | 8.6% four weeks ago; next at the three-month review |
| Laboratory | Lipid panel after starting a statin | 4 to 12 weeks after a statin starts or changes | Due | Atorvastatin started four weeks ago; draw within the next eight weeks |
| Examination | Blood pressure, weight, and BMI | Every visit | Completed today | Seated 142/78 mmHg; weight 95.0 kg, down 1 kg |
| Examination | Lying, seated, and standing blood pressure | Every visit | Completed today | Lying 150/84, standing 110/68 mmHg; heart rate 76 to 80. Baseline before midodrine |
| Examination | Foot examination (inspection, pulses, monofilament) | Every visit with loss of protective sensation | Completed today | No ulcer; sensory loss unchanged |
| Examination | Tonometry (eye pressure) | Every glaucoma visit; 4 to 6 weeks after adding a drop | Deferred | Not measured at this visit, and no eye-clinic check has been booked since dorzolamide was added four weeks ago, a deviation from the plan. Request sent to the eye clinic |
| Survey | Hypoglycemia review and home glucose log | Every visit | Completed today | No readings below 70 mg/dL and no symptoms of low glucose |
| Survey | Tobacco use | Every visit | Completed today | No tobacco use |
| Medication safety | Metformin, atorvastatin, and dorzolamide tolerance | After each start or dose change | Completed today | No stomach upset, muscle aches, or eye stinging |
| Medication safety | Antihypertensive and other medicines that lower standing pressure | Every visit with orthostatic hypotension | Completed today | None in use; timolol and brimonidine avoided |
| Referral | Endocrinology consultation | When the diagnosis or treatment of a complication is uncertain | Completed today | Seen today: diabetic autonomic neuropathy confirmed as the working diagnosis, sitagliptin and midodrine started |
| Self-management | Orthostatic hypotension measures and foot self-care | Every visit | Completed today | Staged standing, head-of-bed elevation, compression, fluids, and daily foot checks reviewed |

## Goal progress

- Reach an HbA1c below 7.5% without hypoglycemia by the six-month review. In progress; target 2026-08-14. **S**
- No falls and a standing systolic pressure of 100 mm Hg or more by the six-month review. In progress; target 2026-08-14. **S**
- Lower intraocular pressure to 16 mm Hg or less in each eye by the three-month review. In progress; target 2026-05-29. **S**
- LDL cholesterol below 70 mg/dL by the six-month review. In progress; target 2026-08-14. **S**

## Medication changes

- Started: Sitagliptin 100 mg oral tablet, one tablet by mouth daily **S**
- Started: Midodrine 2.5 mg oral tablet, one tablet by mouth three times daily, last dose by 6 PM **S**

## Guideline basis

- Standards of Care in Diabetes—2025 (2025), American Diabetes Association
- Primary Open-Angle Glaucoma Preferred Practice Pattern (2025), American Academy of Ophthalmology
- CMID: Clinical Monitoring Intelligence Database, diabetes, glaucoma, and hyperlipidemia monographs (2026), Aether Forge

## Follow-up

- Annual wellness visit in four weeks. Three-month review with HbA1c, lipids, and an eye pressure check. **S**
- Next scheduled visit 2026-04-24: subsequent annual wellness visit. **S**
